| Medical and Health Sciences | 2021-2025 | 195 | FR 5 | 99.96 |
| Pulmonary and Respiratory Medicine | Lifetime | 296 | FR 15 | 99.63 |
| Clinical Neurology | Lifetime | 379 | FR 10 | 98.46 |
| Oncology | Lifetime | 683 | FR 29 | 98.65 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 22 | FR 4 | 99.90 |
| Oncology | 2021-2025 | 54 | FR 6 | 99.72 |
| Clinical Neurology | 2021-2025 | 72 | FR 3 | 98.44 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 541 | FR 9 | 88.71 |
| Myasthenia Gravis and Thymoma | Lifetime | 16 | FR 1 | 99.47 |
| Lung Cancer Treatments and Mutations | Lifetime | 141 | FR 8 | 99.60 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 154 | FR 5 | 99.48 |
| Lung Cancer Research Studies | Lifetime | 199 | FR 14 | 99.15 |
| Pituitary Gland Disorders and Treatments | Lifetime | 166 | FR 13 | 98.94 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 503 | FR 41 | 98.87 |
| Neuroblastoma Research and Treatments | Lifetime | 234 | FR 15 | 98.52 |
| Cancer Diagnosis and Treatment | Lifetime | 322 | FR 18 | 98.21 |
| Colorectal Cancer Treatments and Studies | Lifetime | 469 | FR 34 | 98.59 |
| Cancer Genomics and Diagnostics | Lifetime | 879 | FR 39 | 98.46 |
| Medical Imaging and Pathology Studies | Lifetime | 612 | FR 31 | 97.07 |
| Meningioma and schwannoma management | Lifetime | 493 | FR 20 | 97.45 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 10 | FR 1 | 99.83 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 2 | FR 1 | 99.49 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 22 | FR 4 | 99.86 |
| Neuroblastoma Research and Treatments | 2021-2025 | 7 | FR 1 | 99.13 |
| Lung Cancer Research Studies | 2021-2025 | 21 | FR 2 | 99.68 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 104 | FR 12 | 99.58 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 31 | FR 3 | 99.50 |
| Cancer Genomics and Diagnostics | 2021-2025 | 131 | FR 8 | 98.95 |
| Cancer Diagnosis and Treatment | 2021-2025 | 97 | FR 6 | 93.18 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 197 | FR 10 | 95.52 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 521 | FR 17 | 95.98 |
| Pituitary Gland Disorders and Treatments | 2021-2025 | 170 | FR 13 | 95.69 |
| HER2/EGFR in Cancer Research | 2021-2025 | 317 | FR 19 | 94.85 |
| Meningioma and schwannoma management | 2021-2025 | 594 | FR 33 | 88.45 |
| Peptidase Inhibition and Analysis | 2021-2025 | 963 | FR 23 | 86.15 |
| Occupational and environmental lung diseases | 2021-2025 | 324 | FR 17 | 85.02 |
| Salivary Gland Tumors Diagnosis and Treatment | 2021-2025 | 589 | FR 24 | 80.40 |
| Medical Imaging and Pathology Studies | 2021-2025 | 920 | FR 38 | 73.63 |
